Journal
CURRENT OPINION IN PULMONARY MEDICINE
Volume 16, Issue 2, Pages 123-133Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCP.0b013e328336438d
Keywords
chronic obstructive pulmonary disease; muscle dysfunction; muscle wasting; systemic effects
Categories
Funding
- Spanish Ministry of Industry [TSI-020110-2009-431]
- The Chief Scientist Office, Scotland [06/S1103/5]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072282] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Purpose of review The purpose of this review is to identify new advances in our understanding of skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease (COPD). Recent findings Recent studies have confirmed the relevance of muscle dysfunction as an independent prognosis factor in COPD. Animal studies have shed light on the molecular mechanisms governing skeletal muscle hypertrophy/atrophy. Recent evidence in patients with COPD highlighted the contribution of protein breakdown and mitochondrial dysfunction as pathogenic mechanisms leading to muscle dysfunction in these patients. Summary COPD is a debilitating disease impacting negatively on health status and the functional capacity of patients. COPD goes beyond the lungs and incurs significant systemic effects among which muscle dysfunction/wasting is one of the most important. Muscle dysfunction is a prominent contributor to exercise limitation, healthcare utilization and an independent predictor of morbidity and mortality. Gaining more insight into the molecular mechanisms leading to muscle dysfunction/wasting is key for the development of new and tailored therapeutic strategies to tackle skeletal muscle dysfunction/wasting in COPD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available